CVS Caremark’s Policy Shift On Humira Biosimilars May Not Be What The Doctor Ordered
CVS Caremark changed its formulary to favor Hyrimoz. But this may not be what policymakers had in mind ten years ago when they first thought about biosimilar competition.

What's Your Reaction?






